2 / 21
Volume 09
Journal of Addiction Research & Therapy
Addiction Summit 2018
May 17-18, 2018
Page 18
Notes:
conference
series
.com
May 17-18, 2018 Singapore
8
th
International Conference on
Addictive Disorders and Alcoholism
Drug of abuse testing for synthetic cannabinoids and psychoactive drugs
T
his presentation provides an insight into synthetic cannabinoids; what they are, how they work and their mind altering
impact on drug users. The presentation will take a look at the 7 major structural groups for synthetic cannabinoids and
associated effects. The author will also discuss the new psychoactive substances and the evolution of these drugs in our society
as well as address suitable drug testing techniques available for these products. The presentation takes a look at the features and
benefits, analytical specificity, analytical selectivity and drug testing matrices. This presentation also shares which synthetic and
psychoactive drugs we can currently test and provide a solution for to our stakeholders, employers and corporate customers.
Biography
Colin LaGalia is the Regional Business Director, Toxicology for the Asia Pacific, China and Japan Region, based in Singapore. He has worked extensively across
the Asia Pacific, North Asia, China and Japan regions in both Corporate Commercial and Consulting roles for the past 15 years with strong established business
relationships. He is responsible for providing guidance and direction on all toxicology related matters within the region, including drug and alcohol testing, product
knowledge, product training and sales and marketing support and key opinion leader advocacy. He has a passion developing people capability and advocates for
the importance of drug and alcohol screening to ensure safety on our roads and in our workplaces to reduce accidents and save lives. He works with the APAC
Country Leaders, Toxicology Leads and the Toxicology Global Business Community to identify and develop drug and alcohol testing policies and procedures at
government, police and corporate levels.
Colin.LaGalia@alere.comColin LaGalia
Abbott, Singapore
Colin LaGalia, J Addict Res Ther 2018, Volume 9
DOI: 10.4172/2155-6105-C1-036